drugset / Trial / NCT00156949

EPO Deep Tank in Dialysis Subjects

NCT00156949

Phase 3 Completed 580 enrolled Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Subject incidence of adverse events

Timeline

Start
2005-04
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic